Achilles Therapeutics AI-Powered Precision Cell Therapy Targeting All Tumor Cells March 2023 Non-Confidential © Achilles Therapeutics plc 2023 Forward-Looking Statements / Disclaimers This presentation contains “forward-looking statements,” including statements regarding the proposed development plans and timelines for the Company’s product candidates and the success, cost and timing of its research activities and clinical trials. Forward-looking statements can generally be identified by the use of words su ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commissi ...

Achilles Therapeutics AI-Powered Precision TIL Therapy April 2022 © Achilles Therapeutics plc 2022 Forward-Looking Statements This presentation contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 * Not for trading, but only in connection with the registration of the American Depositary Shares. Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ S ...

Summary of Achilles Therapeutics plc Conference Call Company Overview - **Company**: Achilles Therapeutics plc (NASDAQ: ACHL) - **Focus**: Development of precision T cell therapy targeting solid tumors, leveraging tumor evolution research [4][5] Industry Context - **Industry**: Immuno-oncology, specifically focusing on TIL (tumor-infiltrating lymphocyte) therapies for solid tumors [11] Core Points and Arguments 1. **Clinical Trials**: Updates were provided on ongoing Phase 1/2 clinical trials, specifically the CHIRON and THETIS trials, which are exploring the efficacy of cNeT (clonal neoantigen-reactive T cells) therapy [10][11] 2. **Technology Differentiation**: Achilles utilizes a proprietary VELOS manufacturing process that enhances the potency and specificity of TIL therapies by targeting clonal neoantigens unique to each patient's tumor [6][24] 3. **TRACERx Study**: Exclusive access to the TRACERx study, which has collected extensive genomic data from over 780 non-small cell lung cancer patients, is a significant asset for neoantigen prediction [9] 4. **Early Clinical Data**: Initial results from the first eight patients showed that 88% had detectable cNeT reactivity, with 63% achieving stable disease, indicating potential efficacy [13][14] 5. **Safety Profile**: The therapy demonstrated a manageable toxicity profile, with no higher-grade adverse events reported compared to standard therapies [13] 6. **Process Improvements**: Transitioning to VELOS Process 2 is expected to increase the median cNeT dose by 18-fold compared to Process 1, enhancing the therapeutic potential [20][23] 7. **Future Expectations**: Plans to explore higher doses and combination therapies with immune checkpoint inhibitors in upcoming studies [15][17] Important but Overlooked Content 1. **Financial Position**: As of September 30, the company reported a cash balance of $282 million, providing a runway for ongoing trials and manufacturing scale-up [26] 2. **Regulatory Submissions**: The company plans to file an IND for head and neck squamous cell carcinoma and present GMP data at the December ESMO immuno-oncology meeting [25][23] 3. **Patient Access to Tumor Samples**: Challenges exist in accessing post-treatment tumor samples for analysis, which could provide insights into T cell infiltration and efficacy [50][51] Conclusion Achilles Therapeutics is positioned to advance the field of immuno-oncology through its innovative approach to TIL therapy, focusing on clonal neoantigens and leveraging proprietary manufacturing processes. The early clinical data and ongoing trials suggest promising potential for improved patient outcomes in solid tumors.